{"slideshow_credits": null, "snippet": "Regulators approved Pfizer\u2019s Xeljanz treatment, which is now poised to compete with Abbott Laboratories\u2019 top-selling Humira.", "abstract": "Regulators approve Pfizer's Xeljanz treatment for rheumatoid arthritis, one of company's potentially most lucrative experimental drugs; approval means Pfizer is now poised to compete with Abbott Laboratories' top-selling Humira.", "section_name": "Business Day", "print_page": "7", "document_type": "article", "byline": {"person": [], "organization": "REUTERS", "original": "By REUTERS", "contributor": ""}, "web_url": "http://www.nytimes.com/2012/11/07/business/fda-clears-a-pfizer-treatment-for-rheumatoid-arthritis.html", "lead_paragraph": "Regulators approved Pfizer\u2019s Xeljanz treatment, which is now poised to compete with Abbott Laboratories\u2019 top-selling Humira.", "headline": {"main": "F.D.A. Clears a Pfizer Treatment for Rheumatoid Arthritis", "print_headline": "F.D.A. Clears a Pfizer Treatment for Rheumatoid Arthritis"}, "_id": "509e542100315214fbb78eb0", "word_count": "206", "multimedia": [], "pub_date": "2012-11-07T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Rheumatoid Arthritis", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Abbott Laboratories", "name": "organizations", "is_major": "N", "rank": "3"}, {"value": "Pfizer Inc", "name": "organizations", "is_major": "Y", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "News"}